USING MESENCHYMAL STEM CELLS TO TREAT FEMALE INFERTILITY: AN UPDATE ON FEMALE REPRODUCTIVE DISEASES A REVIEW ARTICLE

Shikha Gupta[1*], Manju Rajput[2], Tabinda Sultan[3], Bhawna Solanki[4], Nilofar Rasheed[5], Vartika Vishnoi[6], Nittam thakur[7], Jaineeta[8], Liji John[9], Salman Khan[10], Lokesh Kumar Tanwar[11], Nida Haroon[12], Abhishek Lachyan[13], Niharika Tiwari[14]

Abstract:

Female physiological state influences the norm of life and prosperity of impacted individuals and couples. Feminine procreative illnesses, like essential female inner conceptive organ inadequacy, polycystic ovary disorder, adenomyosis, Fallopian tube hindrance, and her man condition, will initiate a physiological state. Lately, translational drugs have increased, and a clinical researcher's area unit specializing in treating feminine physiological states exploits novel methodologies. Because of the advantages of practical examples, proliferating sources, and avertible moral issues, Medicinal signaling cells (MSCs) will be used extensively throughout the facility. This paper reviews progressing propels in misleading four MSCs, bone marrow stromal cells, fat-determined immature microorganisms, feminine stream mesenchymal undifferentiated organisms, and channel immature mesenchymal microorganisms. These are utilized for treating female inward conceptual organs and inner regenerative organ sicknesses and supply new methodologies for the therapy of feminine physiological state's satisfaction and prosperity of impacted individuals and couples.

Keywords: Infertility, Mesenchymal, Reproductive disease, Stem Cells

Number: 10.14704/nq.2022.20.7.NQ33314 **Neuro Quantology 2022; 20(7):2424-2432**

INTRODUCTION

Barrenness is illustrated by the inability to achieve any physiological state (counting an unnatural birth cycle) for at least a year. In 2002, 7.4% of married young ladies, or around 2.1 million girls, were clean inside us. The reasons for sterility are separated into three principal classes that the prevalence of which varies: female causes (33 to 41 percent), male causes (25 to 39 percent), and blended causes (9 to 39 percent). Such measurements feature a breathtaking number of women going through sterility.

A few variables are incurring feminine sterility, among which productive framework-related illnesses are the most causes. The pathogenesis for feminine sterility embraces biological process disorders (polycystic ovary syndrome, neural structure pathology, and first female internal reproductive organ insufficiency), bodily structure sterility, pathology, and female internal reproductive organ or cervical sources (cervical pathology, polyps, and tumors).

Endocrine substitution clinical guide is powerful in certain types of sterility, but there's significant evidence from exploratory

***Corresponding Author: -** Shikha Gupta
Address: *1,2,6,8,9,11,14 School of Nursing, Noida International University, Greater Noida (UP), India.
Email: shikha.gupta@niu.edu.in
[3] Center for Translational and Clinical Research, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi.
[13]Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
[4] Department of Radiology, ERA's Medical College & University, Lucknow, India.
[5,7,10] School of Allied Health Sciences, Noida International University, Greater Noida (UP), India.
[12] School of social work (SOSW) at IGNOU, New Delhi, India.
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Examinations that such a clinical guide will expand the opportunity for carcinoma. Natural interaction enlistment, superovulation, or engine helped productive advances have shown patterns toward excessive physiological state rates. In any case, various components of the overstated risks of different pregnancies ought to be examined. These discoveries demonstrate the inadequacies of ongoing therapy regimens.

Researchers have explored elective healing measures, like non-productive clinical guides, the physiological state. Foundational microorganisms are undifferentiated unit cells that can restore themselves for significant stretches while not having essential changes in their overall properties. They will separate into different cell sorts under certain physiological or exploratory circumstances. Given the limitations of exploitation of early-stage and prompted pluripotent immature microorganisms inside the center, there's decent interest in undifferentiated mesenchymal organisms (MSCs), that region unit liberated from every ethical issue and cancer development.

MSCs, furthermore known as mesenchymal stem cells, are non-hematopoietic, undifferentiated organisms that begin in the microbe layer. They have self-re-energizing abilities and division into not only organism layer family lines, for example, chondrocytes, osteocytes, and adipocytes, yet addition the microorganism layer and endodermal cells. MSCs might be collected from numerous adult tissues, similar to myeloid tissue, menorrhea, creature tissue, the fetal layer, and the placenta.

2. REASON FOR INFERTILITY IN FEMALE REPRODUCTIVE ORGANS

Female infertility regenerative body parts include untimely premature ovarian failure (POF), Stein-Leventhal syndrome, adenomyosis, Hydrosalpinx, Intrauterine adhesions, and some less continuous peculiarities contraceptive plot (Figure 1, Table 1).

FIGURE -1

Diagram showing a few potential reasons for female fruitlessness, for example, fallopian tube impediment, adenomyosis, Primary ovarian insufficiency (POI), Sherman disorder, and anemone.

TABLE 1 Reasons for female infertility contraceptive organs

Illness	Pathogenesis	Definition
POF	Hereditary deformities, immune system processes, radiotherapy, diffusion, and diseases	End of ovarian capability after puberty, however before the age of 40, without or with graafian follicles exhaustion
PCOS	Maternal PCOS, intrauterine hyperandrogenism, incendiary adipokines, native beginning a Western eating routine	A complicated issue described by infertility, hirsutism, heftiness, and different feminine unsettling influences
Endometriosis	Oxidative pressure, responsive oxygen species, cell reinforcements, and fiery, hereditary, and imprinting factors	A state where utilitarian mucous membrane is available external to the womb
Uterine tube obstruction	Cyst, tubo ovarian sore	The Tubal impediment is brought about by irritation of the uterine tubes or serous membrane
AS	Injury, contamination, inadequate degree of progesterone, rehashed and forceful operation, extreme endomyometritis	Non Appearance of a typical opening in the cavum of the female genital lot, from the oviduct cylinders to the vagina

3. MESENCHYMAL STEM CELLS

To manage the usage of immature mesenchymal microorganisms (MSCs), the Mesenchymal and Tissue physical cell Committee of the International Society for Cellular clinical Considerations has intended to knish measures to frame human MSCs. In the first place, MSCs ought to be plastic-disciple once kept up with in ordinary cultural conditions. Second, MSCs should be clear-cut CD105, CD73, and CD90 and need articulation of CD45, CD34, CD14, or CD11b, CD79a or CD19, and HLA-DR surface atoms. Third, MSCs should separate into bone-forming cells,lipocytes, and perichondrial cells in vitro. In 2016, the establishment guided adding Master of Science antitumor capability-connected issue discovery like a valuable investigation. the different MSCs to uphold their inventory (figure - 2)



FIGURE -2

The origin of the four sorts of MSCs and the natural belongings of these MSCs. Possible Components have been suggested for ovarian brokenness and uterus tissue treatment. Endocardium development element (VEGF), keratinocytes development element (HGF), Cholinergic neuronal differentiation factor (CDF), changing development element (TGF), B-cell lymphoma 2 (Bcl-2), and network matrix metallopeptidases. Testing ground tests and analytic preliminaries are presently utilizing MSCs, only or in a mix along different medications, for possible appeal to ovarian brokenness and uterus problems. Significantly, restorative meditations for various illnesses in female regenerative organs are causing extraordinary fervor. All the more critically, these investigations give a positive exploratory model for explaining the hidden system involving MSCs for serving feminine barrenness. It gives the hypothetical premise for additional examinations and clinical treatment with MSCs.

TABLE 2 Utilization of MSC treatment in the medication of female contraceptive conditions.

MSC types	Disease		Treatment	Model	Main results	References
Myeloid tissue stromal cells	Ovarian dysfunction	CTX-induced ovarian failure	Intravenous injection	Rabbit	Ovarian function ↑	31
		CTX-induced ovarian failure	Local injection	Mice	Restore ovarian hormone production	34
	Endometrial disorders	24-gauge needle-induced AS	Labeled with SPIOs local/tail vein injection	Mice	Endometrial proliferation ↑	41
		Refractory AS	Uterine artery injection	Human	Reconstruct the endometrium	40
Adipose-derived stem cells	Ovarian dysfunction	Cisplatin-induced ovarian failure	Local injection	Mice	Ovarian function ↑	49
		TG-induced ovarian damage	Collagen scaffold	Rat	Fertility ↑	51
	Endometrial disorders	Trichloroacetic acid-induced AS	Intraperitoneal injection	Rat	Fibrosis ↓, endometrial proliferation ↑	52
MB-MSCs	Ovarian dysfunction	CTX-induced POF	Local injection	Mice	Ovarian weight ↑, hormone secretion ↓	59
		Cisplatin-induced POF	Local injection	Mice	Ovarian function ↑, fibroblast growth factor 2 ↑	62
	Endometrial disorders	Severe AS	Convey through the cervix to the fundus of the uterus	Human	Endometrial thickness ↑	70
		Mechanical injured-induced intrauterine adhesion	Local injection	Rat	Pregnancy rate ↑	77
UC-MSCs	Ovarian dysfunction	CTX-induced POF	Tail vein injection	Mice	Weight of the ovaries ↑, estradiol ↑,	80
		Paclitaxel-induced POF	Local injection	Rat	Follicle-stimulating hormone ↓, estradiol ↑, ovarian function ↑	81
		Perimenopausal ovary	Tail vein injection	Rat	Estradiol ↑, follicle-stimulating hormone ↓, follicle number ↑	85
		Busulfan CTX-induced premature ovarian insufficiency	Local injection	Mice	Fertility ↑, ovarian functions ↑	77
	Endometrial disorders	Uterine niche	Local intramuscular injection	Human	Uterine scar reconstruction ↑, uterine niche incidence ↓	91
		95% ethanol-induced endometrial injury	Tail vein injection	Rat	Fertility ↑, endometrial fibrosis ↓, angiogenesis ↑	87

CTX: Cytoxan TG: Tripterygium glycosides; ↑: increase; ↓: decrease.

For ovarian disturbance, MSCs can straightforwardly and quickly move to the hurt ovary and get there below the sensation of different components that work with ovarian recuperation. According to accessible assessments, the amount of isolated and organized MSCs is negligible to get a handle on the upgrade in ovarian capacity. Additionally as long as MSCs partition into egg cells following moving to hurt substance is indistinct. Paracrine frameworks might drive work on ovarian ability in these assessments. These parts incorporate the release of explicit lymphokine, including vascular endothelial improvement element, insulin-like advancement factor, and liver cell advancement element, that are cooperative for maturation, threatening irritation, antitumor, antiapoptosis, and against fibrosis to help ovarian modification.

More investigations are expected to investigate like MSCs separate into goal cells like immature ovum that further develop sex organ capabilities and eventually right sex organ pathology. Such separation would try to be significant for an MSc move applied as a clinical consideration. MSCs further develop the mucosa hold, that relies on situating and paracrine exercises. In examinations until this point, it's by and extensive recognized that the paracrine effect of MSCs is the most huge, rather

than separation. In particular, the regenerative properties of relocated MSCs are ascribed to components that include cell contact and emission of bioactive atoms that advance ontogenesis and tissue fix, subsequently restraining scarring, regulating inflammatory and resistant responses, and enacting tissue-explicit better cells. Nonetheless, unique examination recommends that MSCs engraft the mucous film in rodents and people, where they become creature tissue, stromal, and epithelial tissue cells. In this way, MSCs would conceivably advance mucosa recovery and reestablish richness by paracrine factors, but various components are conceivable.

3.1. BONE MARROW STROMAL CELLS

At first portrayed by Owen and Friedenstein in 1988, bone marrow stromal cells were isolated from nucleated bone marrow cells on plastic culture dishes by thickness angle centrifugation. These cells had a more extended replication cycle and untimely infirmity, representing just 0.01-0.001% of nucleated bone marrow cells. Bone marrow stromal cells, the primary wellspring of multipotent undifferentiated organisms, act as a norm for examination with MSCs from different sources. Bone marrow stromal cells focus on osteoblasts, adipocytes, and chondroblasts yet separate into granulosa, endometrial, and endothelial cells in vertebrates. Besides, bone marrow stromal cells have expansive application possibilities in the field of regenerative medication, including conceptive dysfunction.

3.1.1. APPLICATION OF BONE MARROW STROMAL CELLS TO TREAT OVARIAN DYSFUNCTION

A couple of assessments have shown gainful effects of bone marrow stromal cell treatment in a chemotherapy-provoked ovarian frustration animal model. Specifically, the results showed the way that ovarian plan and work could be restored by bone marrow stromal cells. Despite the fact that CTX prescriptions can curb the advancement of development cells, they can in like manner brief Follicular cells apoptosis, follicular atresia, ovarian ability decline, and various appearances of troublesome ovarian frustration. Follicular cells, arranged on the level side of the oocyte zona pellucida and emanate estrogen under the action of follicle-vivifying synthetics and other paracrine factors, expect a section in the sustenance and support of oocytes. Follicular cells, apoptosis thus prompts a decrease in estrogen levels in the body, impacting the regular improvement of gamete.

3.2. ADIPOSE-DERIVED STEM CELLS

Fat-determined foundational microorganisms, another kind of MSC, have been utilized fundamentally to fix issues. Although these cells have similar biologic attributes as bone marrow stromal cells, they are more straightforward to separate in massive amounts (by negligibly obtrusive lipoplasty) than bone marrow stromal cells. Consequently, differentiated and bone marrow stromal cells and fat-decided juvenile microorganisms address a more sound decision.

Renowned et al. exhibited that fat-determined foundational microorganism treatment further developed ovarian join quality by advancing an expansion in vascular endothelial development factor-A quality articulation and the number of veins in ovarian tissue to prompt an initial presumption of capability in newly ground ovaries of grown-up female rodents. Furthermore, fat-determined undeveloped cells improved CTX-prompted ovarian brokenness in mouse models. They were fit for actuating ontogeny and reestablishing the number of graafian follicles and corpus luteum graviditatis in harmed ovaries. Another test, using a cavia porcellus model of untimely ovarian dearth, confirmed that adding a hyaluronan framework upgraded the transient support of fat-determined foundational microorganisms in ovaries, contrasting and relocating these cells individually. In one more trial rodent replica, the utilization of estradiol in a blend with fat determined not different cells effectively actuated recovery of the endometrium in Asherman condition treatment.

3.3. MENSTRUAL BLOOD MESENCHYMAL STEM CELLS (MB-MSCS)

Feminine blood mesenchymal undifferentiated organisms (MB-MSCs) can be disengaged from feminine blood. These cells have high proliferative, restraint, and various separation possibilities. Moreover, they seem to have

multiple benefits over undeveloped cells from different origins, including clarity of assortment, protected and painless expansion, no ethical worries, and no resistant system dismissal reactions. A few clinical preliminaries have utilized MB-MSCs to treat forebrain infections, diabetes mellitus, and numerous inductions.

3.3.1. APPLICATION OF MB-MSCS TO TREAT OVARIAN DYSFUNCTION

A couple of assessments have shown that MB-MSCs decrease apoptosis in follicular cells and fibrosis of the ovarian interspatial, improving luteinization and saving, as a rule, capacity in an animal model of POF, including restoring extravagance. Moreover, Wang et al. showed that MB-MSCs made a severe fibroblast advancement factor 2, which further developed cell perseverance, extension, and capacity to fix tissue pain. Besides, Yan et al. exhibited that MB-MSCs diminished granulosa cell apoptosis and chipped away at ovarian accommodations in mice by adverse impact Gadd45b protein enunciation (a strain sensor whose effects are interceded through actual participation with other cell proteins entangled in cell cycle rules) and up controlling cyclinB1 and CDC2 (regulators of the G2/M change in mammalian cells).

3.3.2. Application of MB-MSCs to Treat Endometrial Disorders

MB-MSCs restricted from ectopic endometriotic wounds add to the pathogenesis of endometriosis. A clinical report where autologous MB-MSCs were migrated into seven patients with extreme Asherman condition, followed by hormonal inclination, showed that the thickness of the mucous membrane in five women showed up at 7 mm, one patient had an unconstrained pregnancy, and two of the plethora four patients going through lacking life form move became pregnant.

In rodents with hurt endometrium (an Asherman condition model), MB-MSCs accumulated into spheroids and further created readiness by growing the mix of antigenic and quieting factors. The essential properties of MB-MSCs were held in the spheroids, besides the statement of CD146 that antagonistically compared with the self-capacity to re-energize. It is crucial to chip away at the beneficial effect of MB-MSCs facilitated into ellipsoidal.

Zheng et al. quickly demonstrated that MB-MSCs could separate into mucosa cells in vitro and reconstruct mucosa tissue in NOD-SCID mice in the wake of regulating estrogen and progestins in vivo. POU5F1 positive cells can separate into three microorganism layers as a record factor. Besides, the imitating proficiency and POU5F1 articulation of MB-MSCs from patients with extreme intrauterine bonds were diminished, contrasted, and controlled.

Platelet-rich plasma (PRP), an autologous plasma item with platelet focus above standard qualities, has been utilized to treat intense and ongoing wounds. Zhang et al. looked at fake treatment, MB-MSC transplantation, PRP transplantation, and consolidated MB-MSC and PRP transplantation in treating a rodent model of the intrauterine bond. They observed that joining MB-MSCs with PRP was more potent than either treatment alone in working on endometrial multiplication, apoptosis, and morphological recovery. This treatment likewise diminished fibrosis and irritation by changing the Hippo flagging pathway and directing the downstream factors, connective tissue development factor.

3.4. UMBILICAL CORD MESENCHYMAL STEM CELLS

Umbilical cord mesenchymal stem cells (UC-MSCs), separated from Wharton's jam of the UC, are called human Wharton's jam MSCs. They express the MSC markers CD29, CD44, CD73, CD90, and CD105 and don't communicate CD31, CD45, and HLA-DR85. Since they have lower tumorigenic and quicker establishment capacities contrasted with different wellsprings of MSCs, UC-MSCs are another wellspring of immature microorganisms that can separate into a few mesoblastic cell types and be utilized for cell treatment.

3.4.1. APPLICATION OF UC-MSCS TO TREAT OVARIAN DYSFUNCTION

UC-MSCs have been utilized in a few creature models to effectively treat POF by lessening apoptosis of follicular cells, diminishing follicle-animating chemical serum levels, and expanding estrogen and hostile to Mullerian chemical groups. Elfayomy et al. suggested that

UC-MSCs could switch paclitaxel-initiated apoptosis of ovarian cells either by laying out a typical game plan of the surface epithelium and tunica albuginea, or by helicases cytokeratin 8/18, changing development factor-β, and multiplying cell atomic antigen to smother caspase-3 articulation. In another examination, Jalalie et al. relocated CM-Dill-marked human UC-MSCs into cyclophosphamide-harmed ovaries in mice. They observed that UC-MSCs were not conveyed similarly in that frame of mind of the ovarian tissue. In particular, the quantity of CM-Dill-marked human UC-MSCs in the ovarian medulla was more prominent than in the ovarian cortex and germinal epithelium.

UC-MSCs on a collagen platform have been relocated into ovaries to treat POF. Ding et al. found that this method enacted early-stage follicles in vitro using phosphorylation of FOXO3a, an effective silencer of early-stage follicle enactment, and FOXO1. Li et al. found that human UC-MSCs used to treat perimenopausal rodents emitted cytokines, for example, hepatocyte development factor, vascular endothelial development element, and insulin-like development factor-1, bringing about better ovarian save capabilities.

3.4.2. APPLICATION OF UC-MSCS TO TREAT ENDOMETRIAL DISORDERS

Wharton's jam inferred that MSCs could isolate into endometrial cells. In a rat model, Zhang et al. found that human UC-MSCs fixed hurt endometrium, further creating productivity. These experts, like manner, say that the amount of implanted lacking living beings was higher in bundles with various UC-MSC transplantations diverged from lone UC-MSC transplantation by overexpressing vascular and downregulating cytokines factors. Additionally, UC-MSCs in collagen structures have been used to progress endometrial recuperation by overexpressed network metalloproteinase-9 in rat uterine scars.

UC-MSCs can decrease damage to human endometrial stromal cells, and the close-by intramuscular mixture is viable for treating uterine claims to fame following cesarean conveyance. Moreover, in stage, I clinical preliminaries, UC-MSCs on collagen stages were utilized to treat patients with tedious uterine bonds. The discoveries proposed that they can influence mucosa extension, detachment, and angiogenesis by expanding estrogen receptor, vimentin, Ki67, and von Willebrand factor articulation levels while diminishing NP63 articulation levels.

4. CONCLUSIONS AND FUTURE PERSPECTIVES

MSCs have a pleasant possible comfort for caring for feminine physiological states in creatures and individual examinations. Homologous fat inferred undeveloped follicles are beneficial because they're not exclusively essentially acquired but also stay away from uniting dismissal once transplantation. In late years, autologous fat determined physical cell transplantation or infusion meaningfully affects rodent models of POF and Asherman disorder and may increment treatment rates. There are numerous principal headings for double-dealing MS to treat unfruitful young ladies brought about by sex organ, or female inner conceptive organ factors: (1)

Most examinations are finished on little creatures. There's a weighty absence of significant investigation in huge creature models that intently copy the sex organ or mucosa pathophysiology of the individual feminine physiological state. Furthermore, an irregular controlled primer should be directed to check the reasonable outcome of MSCs in readiness drugs. (2)

The component of MSCs in treating the condition of female productive organs stays obscure. Possibilities typify advancing turn of events, separating into viable cells and a paracrine part. A paracrine function can be crucial for feminine physiological state treatment. Nonetheless, supportive paracrine factors stay obscure and different systems are likewise synergistic. (3)

Though MS clinical guide is promising, bioactive specialists' limited endurance and engraftment because of threatening environmental elements might be a bottleneck for illness treatment. Thus, the technique for staying aware of and working on the perseverance and emanation of MSCs over a long proportion of your time needs a lot of comprehensive examination. One methodology that amplifies the use of MSCs for sex organ and mucosa problems has been the occasion of arranged sorts of biocompatibility. Hyaluronan-based biocompatibility has

previously been utilized in MS conveyance agents to support follicle grip and maintenance. No different either way; additional work is expected to upgrade this methodology.

Declaration

Some other sources did not uphold this study. The creators have pronounced no irreconcilable circumstances, Consent to take part, and morals endorsement. This assessment doesn't need moral approval because no persistent information will be gathered. Counterfeiting, privacy, wrongdoing, information adulteration or potentially misrepresentation, twofold distributing and additional accommodation, and duplication are moral issues that the creator has wholly analyzed in this work.

Affirmations First and preeminent, I need to offer my thanks to God for permitting me the chance to attempt and finish this exploration project for my scholastic accomplishment. I might want to thank and show gratitude to my coach for empowering and directing me during the most common way of composing this post, who had committed their significant opportunity to help me, either straightforwardly or in a roundabout way, during the journey. I might want to offer my sincere thanks to every one of my companions for their unflinching help and help to finish this review. Finally, I might like to thank my family for their affection, persistence, and backing during the review cycle.

REFERENCES:

Hull M. G., Glazener C. M., Kelly N. J., et al. Population study of causes, treatment, and outcome of infertility. *BMJ.* 1985;291(6510):1693–1697. DOI: 10.1136/bmj.291.6510.1693. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Chandra A., Martinez G. M., Mosher W. D., Amba J. C., Jones J. Fertility, family planning, and reproductive health of U.S. women; data from the 2002 National Survey of Family Growth. *Vital and Health Statistics.* 2005;23(25):1–160. DOI: 10.1037/e414702008-001. [PubMed] [CrossRef] [Google Scholar]

Deroux A., Dumestre-Perard C., Dunand-Faure C., Bouillet L., Hoffmann P. Female infertility and serum auto-antibodies: a systematic review. *Clinical Reviews in Allergy and Immunology.* 2017;53(1):78–86. DOI: 10.1007/s12016-016-8586-z [PubMed] [CrossRef] [Google Scholar]

Holmberg L., Iversen O. E., Rudenstam C. M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *JNCI: Journal of the National Cancer Institute.* 2008;100(7):475–482. doi: 10.1093/jnci/djn058. [PubMed] [CrossRef] [Google Scholar]

Vermeulen R. F. M., Korse C. M., Kenter G. G., Brood-van Zanten M. M. A., van Beurden M. Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. *Climacteric.* 2019;22(4):352–360. DOI: 10.1080/13697137.2019.1582622 [PubMed] [CrossRef] [Google Scholar]

Practice Committee of the American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. *Fertility and Sterility.* 2012;97(4):825–834. doi: 10.1016/j.fertnstert.2011.11.048. [PubMed] [CrossRef] [Google Scholar]

Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. *Advances in Cancer Research.* 2008;100(8):133–158. doi: 10.1016/S0065-230X(08)00005-5. [PubMed] [CrossRef] [Google Scholar]

Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* 2006;8(4):315–317. doi: 10.1080/14653240600855905 [PubMed] [CrossRef] [Google Scholar]

Dezawa M., Ishikawa H., Itokazu Y., et al. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. *Science.* 2005;309(5732):314–317. doi: 10.1126/science.1110364. [PubMed] [CrossRef] [Google Scholar]

Salem H. K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells.* 2010;28(3):585–596. doi: 10.1002/stem.269. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Körbling M., Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? *Blood.* 2001;98(10):2900–2908. doi: 10.1182/blood.V98.10.2900. [PubMed] [CrossRef] [Google Scholar]

Meng X., Ichim T. E., Zhong J., et al. Endometrial regenerative cells: a novel stem cell population. *Journal of Translational Medicine.* 2007;5(1):1–10. DOI: 10.1186/1479-5876-5-57. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Barry F. P., Murphy J. M. Mesenchymal stem cells: clinical applications and biological characterization. *The International Journal of Biochemistry & Cell Biology.* 2004;36(4):568–584. doi: 10.1016/j.biocel.2003.11.001. [PubMed] [CrossRef] [Google Scholar]

Lee O. K., Kuo T. K., Chen W.-M., Lee K.-D., Hsieh S.-L., Chen T.-H. Isolation of multipotent mesenchymal stem cells from umbilical cord

blood. *Blood.* 2004;103(5):1669–1675. doi: 10.1182/blood-2003-05-1670. [PubMed] [CrossRef] [Google Scholar]

in't Anker P. S., Scherjon S. A., der Keur C. K.-v., et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells.* 2004;22(7):1338–1345. doi: 10.1634/stemcells.2004-0058. [PubMed] [CrossRef] [Google Scholar]

Krampera M., Galipeau J., Shi Y., Tarte K., Sensebe L., MSC Committee of the International Society for Cellular Therapy (ISCT) Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. *Cytotherapy.* 2013;15(9):1054–1061. DOI: 10.1016/j.jcyt.2013.02.010. [PubMed] [CrossRef] [Google Scholar]

Galipeau J., Krampera M., Barrett J., et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. *Cytotherapy.* 2016;18(2):151–159. doi: 10.1016/j.jcyt.2015.11.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Naji A., Rouas-Freiss N., Durrbach A., Carosella E. D., Sensébé L., Deschaseaux F. Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy. *Stem Cells.* 2013;31(11):2296–2303. DOI: 10.1002/stem.1494. [PubMed] [CrossRef] [Google Scholar]

Squillaro T., Peluso G., Galderisi U. Clinical trials with mesenchymal stem cells: an update. *Cell Transplantation.* 2016;25(5):829–848. doi: 10.3727/096368915X689622. [PubMed] [CrossRef] [Google Scholar]

Galipeau J., Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell.* 2018;22(6):824–833. doi: 10.1016/j.stem.2018.05.004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Trounson A., McDonald C. Stem cell therapies in clinical trials: progress and challenges. *Cell Stem Cell.* 2015;17(1):11–22. doi: 10.1016/j.stem.2015.06.007. [PubMed] [CrossRef] [Google Scholar]

Owen M., Friedenstein A. J. Stromal stem cells: marrow-derived osteogenic precursors. *Ciba Foundation Symposium.* 1988;136:42–60. doi: 10.1002/9780470513637.ch4. [PubMed] [CrossRef] [Google Scholar]

Altaner C., Altanova V., Cihova M., et al. Characterization of mesenchymal stem cells of "no-options' ' patients with critical limb ischemia treated by autologous bone marrow mononuclear cells. *PLoS One.* 2013;8(9, article e73722):9. doi: 10.1371/journal.pone.0073722. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Yun Cheng H. The impact of mesenchymal stem cell source on proliferation, differentiation, immunomodulation and therapeutic efficacy. *Journal of Stem Cell Research & Therapy.* 2014;04(10) doi: 10.4172/2157-7633.1000237. [CrossRef] [Google Scholar]

Ullah I., Subbarao R. B., Rho G. J. Human mesenchymal stem cells - current trends and future prospective. *Bioscience Reports.* 2015;35(2):1–18. doi: 10.1042/bsr20150025. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Besikcioglu H. E., Sarıbas G. S., Ozogul C., et al. Determination of the effects of bone marrow derived mesenchymal stem cells and ovarian stromal stem cells on follicular maturation in cyclophosphamide induced ovarian failure in rats. *Taiwanese Journal of Obstetrics & Gynecology.* 2019;58(1):53–59. doi: 10.1016/j.tjog.2018.11.010. [PubMed] [CrossRef] [Google Scholar]

Gao L., Huang Z., Lin H., Tian Y., Li P., Lin S. Bone marrow mesenchymal stem cells (BMSCs) restore functional endometrium in the rat model for severe Asherman syndrome. *Reproductive Sciences.* 2019;26(3):436–444. doi: 10.1177/1933719118799201. [PubMed] [CrossRef] [Google Scholar]

Liu Y., Tal R., Pluchino N., Mamillapalli R., Taylor H. S. Systemic administration of bone marrow-derived cells leads to better uterine engraftment than use of uterine-derived cells or local injection. *Journal of Cellular and Molecular Medicine.* 2018;22(1):67–76. doi: 10.1111/jcmm.13294. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Tepper O. M., Sealove B. A., Murayama T., Asahara T. Newly emerging concepts in blood vessel growth: recent discovery of endothelial progenitor cells and their function in tissue regeneration. *Journal of Investigative Medicine.* 2003;51(6):353–359. doi: 10.1136/jim-51-06-31. [PubMed] [CrossRef] [Google Scholar]

Wei X., Yang X., Han Z. P., Qu F. F., Shao L., Shi Y. F. Mesenchymal stem cells: a new trend for cell therapy. *Acta Pharmacologica Sinica.* 2013;34(6):747–754. doi: 10.1038/aps.2013.50. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Abd-Allah S. H., Shalaby S. M., Pasha H. F., et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. *Cytotherapy.* 2013;15(1):64–75. doi: 10.1016/j.jcyt.2012.08.001. [PubMed] [CrossRef] [Google Scholar]

Badawy A., Sobh M. A., Ahdy M., Abdelhafez M. S. Bone marrow mesenchymal stem cell repair of cyclophosphamide-induced ovarian insufficiency in a mouse model. *International Journal of Women's Health.* 2017;9:441–447. doi: 10.2147/IJWH.S134074. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Fu X., He Y., Wang X., et al. Overexpression of miR-21 in stem cells improves ovarian structure and function in rats with chemotherapy-induced ovarian damage by targeting PDCD4 and PTEN to inhibit granulosa cell apoptosis. *Stem Cell Research & Therapy.* 2017;8(1):p. 187. doi: 10.1186/s13287-017-0641-z.

[PMC free article] [PubMed] [CrossRef] [Google Scholar]

Mohamed S. A., Shalaby S. M., Abdelaziz M., et al. Human mesenchymal stem cells partially reverse infertility in chemotherapy-induced ovarian failure. *Reproductive Sciences.* 2018;25(1):51–63. doi: 10.1177/1933719117699705. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Taylor H. S. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. *Journal of the American Medical Association.* 2004;292(1):81–85. doi: 10.1001/jama.292.1.81. [PubMed] [CrossRef] [Google Scholar]

Panchal S., Patel H., Nagori C. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman's syndrome. *Journal of Human Reproductive Sciences.* 2011;4(1):43–48. doi: 10.4103/0974-1208.82360. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Singh N., Mohanty S., Seth T., Shankar M., Dharmendra S., Bhaskaran S. Autologous stem cell transplantation in refractory Asherman's syndrome: a novel cell based therapy. *Journal of Human Reproductive Sciences.* 2014;7(2):93–98. doi: 10.4103/0974-1208.138864. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Alawadhi F., Du H., Cakmak H., Taylor H. S. Bone marrow-derived stem cell (BMDSC) transplantation improves fertility in a murine model of Asherman's syndrome. *PLoS One.* 2014;9(5):e96662–e96666. DOI: 10.1371/journal.pone.0096662. [PMC free article] [PubMed][CrossRef] [Google Scholar]

Wang J., Ju B., Pan C., et al. Application of bone marrow-derived mesenchymal stem cells in the treatment of intrauterine adhesions in rats. *Cellular Physiology and Biochemistry.* 2016;39(4):1553–1560. doi: 10.1159/000447857. [PubMed] [CrossRef] [Google Scholar]

Santamaria X., Cabanillas S., Cervelló I., et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study. *Human Reproduction.* 2016;31(5):1087–1096. doi: 10.1093/humrep/dew042. [PubMed] [CrossRef] [Google Scholar]

Cervelló I., Gil-Sanchis C., Santamaría X., et al. Human CD133+ bone marrow-derived stem cells promote endometrial proliferation in a murine model of Asherman syndrome. *Fertility and Sterility.* 2015;104(6):1552–1560.e3. doi: 10.1016/j.fertnstert.2015.08.032. [PubMed] [CrossRef] [Google Scholar